CHAIR
:
SPEAKER
(S):
Michael Cleare, , Director, Science & Technology Ventures, Columbia University
Lita Nelsen, Director, MIT Technology Licensing Office
Margaret ("Maggie") Flanagan LeFlore, PhD, Head of R&D Ventures, AstraZeneca, Inc.
Mark Carthy, General Partner, Oxford Bioscience Partners
Description
In response to the all too common view that licensing opportunities arising from academia are too preliminary, many institutions are building biotech-like drug discovery capabilities. The session will review such initiatives, the drivers and the implications as well as explore industry opinion.
Objectives:
Review academic initiatives in drug discovery and development.
Examine the drivers of applied development programs and the likely implications of such activities.
Explore the views held by investors, alliance managers and business development personnel in the biopharmaceutical industry.